期刊文献+

PEA3和GDNF在小鼠纹状体的表达

Expression of Polymoma Virus Enhancer-3 and Glial Cell Line-Derived Neurotrophic Factor in Striatum of Mice
原文传递
导出
摘要 目的:观察多瘤促活化因子(PEA3)和胶质细胞源性神经生长因子(GDNF)蛋白在出生后小鼠纹状体神经纤维中的表达变化及相关性,为进一步探讨多巴胺能神经元疾病的治疗方法提供实验依据。方法:分别取正常鼠龄为1,5,10,20,30,40 d昆明小鼠各5只,断头处死,迅速取出大脑,冠状面切取纹状体所在部位1 cm厚的组织块。常规固定、脱水、石蜡包埋,连续切片,免疫组织化学SABC方法,DAB染色。结果:本实验观察到PEA3免疫阳性反应纤维数目在出生后1,5,10,20 d持续上升,在30,40 d下降并保持在一定水平,GDNF蛋白免疫反应阳性纤维数目在出生后1,5,10,20 d保持在一定水平,在30,40 d下降,各组间的表达差异具有统计学意义(P<0.05)。结论:出生后,GDNF在纹状体多巴胺能神经纤维发育过程中发挥作用,并且可能以PEA3作为其下游作用靶。这种作用方式在第20天以前可能是GDNF作用于纹状体神经纤维发育过程的主要途径。 Objective: To investigate the expression of polymoma virus enhancer-3 (PEA3) and glial cell line-derived neurotrophic factor (GDNF) in striatum of new-born mice. Methods: Kunming mice at age of 1, 5, 10, 20, 30, and 40 days were sacrificed to harvest cerebrum for pathological observation. Immunohistochemistry using the method of SABC was adopted to study the expression of PEA3 and GDNF. Results: The numbers of PEA3 positive fibers increased continuously on 1, 5, 10 and 20 days after born, then decreased to a certain level. The number of GDNF positive fihers kept on a certain level on 1, 5, 10, and 20 days after born and then decreased(P〈0.05). Conclusion.GDNF has an obvious effect on the development dopamine neural fibers after born in mice, especially for the ≤20-day newborns, and maybe PEA3 is its downstream target.
出处 《武汉大学学报(医学版)》 CAS 北大核心 2009年第4期441-443,I0001,共4页 Medical Journal of Wuhan University
关键词 PEA3 GDNF 纹状体 神经发育 Polymoma Virus Enhancer-3 Glial Cell Line-Derived Neurotrophic Factor Striatum Neural Development
  • 相关文献

参考文献2

二级参考文献35

  • 1Rascol O, Payoux P, Ory F, et al.Limitations of current Parkinson's disease therapy.Ann Neurol, 2003,53 Suppl 3:S3- S12.
  • 2Le HN, Frim DM.Gene therapy for Parkinson's disease.Expert Opin Biol Ther, 2002,2:151-161.
  • 3Nutt JG, Obeso JA, Stocchi F.Continuous dopamine-receptor stimulation in advanced Parkinson's disease.Trends Neurosci, 2000, 23:S109-S115.
  • 4Nagatsu T, Ichinose H.Molecular biology of catecholamine-related enzymes in relation to Parkinson's disease.Cell Mol Neurobiol, 1999, 19:57-66.
  • 5Muramatsu S, Wang L, Ikeguchi K,et al.Recombinant adeno-associated viral vectors bring gene therapy for Parkinson's disease closer to reality.J Neurol, 2002, 249 Suppl 2:II36-II40.
  • 6Kirik D, Georgievska B, Burger C,et al.Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.Proc Natl Acad Sci U S A, 2002, 99:4708-4713.
  • 7Bencsics C, Wachtel SR, Milstien S,et al.Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts.J Neurosci, 1996, 16:4449-4456.
  • 8Shen Y, Muramatsu SI, Ikeguchi K,et al.Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.Hum Gene Ther, 2000,11:1509-1519.
  • 9Muramatsu S, Fujimoto K, Ikeguchi K,et al.Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes.Hum Gene Ther, 2002,13:345-354.
  • 10Kang UJ, Lee WY, Chang JW.Gene therapy for Parkinson's disease:determining the genes necessary for optimal dopamine replacement in rat models.Hum Cell, 2001,14:39-48.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部